Similar articles

• Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

  Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Lacouture ME, et al. J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142600 Clinical Trial.
• Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.

  Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A. Eames T, et al. Acta Derm Venereol. 2010 Mar;90(2):202-3. doi: 10.2340/00015555-0792. Acta Derm Venereol. 2010. PMID: 20169314 No abstract available.
• STEPP for the EGFR inhibitor-induced rash--definitely a step in the right direction.

  Coleman S, Jatoi A. Coleman S, et al. Curr Oncol Rep. 2010 Jul;12(4):223-5. doi: 10.1007/s11912-010-0102-7. Curr Oncol Rep. 2010. PMID: 20437117 Free PMC article. No abstract available.
• Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.

  Dunsford J. Dunsford J. Clin J Oncol Nurs. 2008 Jun;12(3):405-7. doi: 10.1188/08.CJON.405-407. Clin J Oncol Nurs. 2008. PMID: 18515238 Review. No abstract available.
• Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.

  Ouwerkerk J, Boers-Doets C. Ouwerkerk J, et al. Eur J Oncol Nurs. 2010 Sep;14(4):337-49. doi: 10.1016/j.ejon.2010.03.004. Epub 2010 May 23. Eur J Oncol Nurs. 2010. PMID: 20580896 Review.